PF-03654746

PF-03654746
(IUPAC) ime
	(1R,3R)-N-etil-3-fluoro-3-[3-fluoro-4-(pirolidin-1-ilmetil)fenil]ciklobutan-1-karboksamid
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	16119086
Hemijski podaci
Formula	C18H24F2N2O
Mol. masa	322,392
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C18H24F2N2O/c1-2-21-17(23)14-10-18(20,11-14)15-6-5-13(16(19)9-15)12-22-7-3-4-8-22/h5-6,9,14H,2-4,7-8,10-12H2,1H3,(H,21,23) ; Key: SXMBKHYDZOCBMT-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

PF-03654746 je potentan i selektivan antagonist histaminskog H₃ receptor koji je razvila kompanija Pfizer i trenutno je u kliničkim ispitivanjima za tretman ADHD-a, Toretovog sindroma,^[3] kao i za potencijalne antialergijske primene.^[4]^[5]^[6]^[7]

Reference[uredi - уреди | uredi kôd]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Pfizer: "Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome", http://clinicaltrials.gov/ct2/show/NCT01475383, accessed 06 Jan 2012
↑ Romero Jr., F. A.; Allan, R. J.; Phillips, P. G.; Hutchinson, K.; Misfeldt, J. M.; Casale, T. B. (2010). „The Effects of an H3 Receptor Antagonist in a Nasal Allergen Challenge Model”. Journal of Allergy and Clinical Immunology 125: AB191. DOI:10.1016/j.jaci.2009.12.750.
↑ Soares, H.; Wager, T. T.; Schmidt, A. W.; Sweeney, F. J.; McLellan, T. J.; Nelson, F. R.; Spracklin, D.; Wang, E. Q. i dr.. (2009). „H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers”. Alzheimer's and Dementia 5 (4): P254. DOI:10.1016/j.jalz.2009.04.272.
↑ Gemkow, M.; Davenport, A.; Harich, S.; Ellenbroek, B.; Cesura, A.; Hallett, D. (2009). „The histamine H3 receptor as a therapeutic drug target for CNS disorders”. Drug Discovery Today 14 (9–10): 509–515. DOI:10.1016/j.drudis.2009.02.011. PMID 19429511.
↑ Wijtmans, M.; Denonne, F.; Célanire, S.; Gillard, M.; Hulscher, S.; Delaunoy, C.; Van Houtvin, N.; Bakker, R. A. i dr.. (2010). „Histamine H3 receptor ligands with a 3-cyclobutoxy motif: a novel and versatile constraint of the classical 3-propoxy linker”. MedChemComm 1: 39. DOI:10.1039/c0md00056f.

Spoljašnje veze[uredi - уреди | uredi kôd]

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Pfizer: "Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome", http://clinicaltrials.gov/ct2/show/NCT01475383, accessed 06 Jan 2012

[4] Romero Jr., F. A.; Allan, R. J.; Phillips, P. G.; Hutchinson, K.; Misfeldt, J. M.; Casale, T. B. (2010). „The Effects of an H3 Receptor Antagonist in a Nasal Allergen Challenge Model”. Journal of Allergy and Clinical Immunology 125: AB191. DOI:10.1016/j.jaci.2009.12.750.

[5] Soares, H.; Wager, T. T.; Schmidt, A. W.; Sweeney, F. J.; McLellan, T. J.; Nelson, F. R.; Spracklin, D.; Wang, E. Q. i dr.. (2009). „H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers”. Alzheimer's and Dementia 5 (4): P254. DOI:10.1016/j.jalz.2009.04.272.

[6] Gemkow, M.; Davenport, A.; Harich, S.; Ellenbroek, B.; Cesura, A.; Hallett, D. (2009). „The histamine H3 receptor as a therapeutic drug target for CNS disorders”. Drug Discovery Today 14 (9–10): 509–515. DOI:10.1016/j.drudis.2009.02.011. PMID 19429511.

[7] Wijtmans, M.; Denonne, F.; Célanire, S.; Gillard, M.; Hulscher, S.; Delaunoy, C.; Van Houtvin, N.; Bakker, R. A. i dr.. (2010). „Histamine H3 receptor ligands with a 3-cyclobutoxy motif: a novel and versatile constraint of the classical 3-propoxy linker”. MedChemComm 1: 39. DOI:10.1039/c0md00056f.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

PF-03654746

Reference[uredi - уреди | uredi kôd]

Spoljašnje veze[uredi - уреди | uredi kôd]

Navigacijski meni

Traži-Тражи